Clinical Scorecard: CGRP Therapies Reduced Migraine Days
At a Glance
| Category | Detail |
|---|---|
| Condition | Chronic Migraine |
| Key Mechanisms | CGRP-targeted therapies |
| Target Population | Adults with chronic migraine (≥15 headache days/month, ≥8 with migraine features) |
| Care Setting | Outpatient |
Key Highlights
- CGRP therapies reduced monthly migraine headache days by about 2 days vs placebo.
- High-certainty evidence for eptinezumab, erenumab, fremanezumab, galcanezumab, and atogepant.
- Fremanezumab and erenumab showed high-certainty evidence for achieving at least a 50% reduction in migraine days.
- Galcanezumab likely reduced dropout rates compared to placebo.
- Erenumab and atogepant likely increased risks of constipation and nausea.
Guideline-Based Recommendations
Diagnosis
- Chronic migraine defined as headache on ≥15 days/month with ≥8 days featuring migraine characteristics.
Management
- Consider CGRP-targeted therapies for chronic migraine prophylaxis.
Monitoring & Follow-up
- Monitor for adverse events, particularly gastrointestinal symptoms.
Risks
- Increased risk of constipation and nausea with erenumab and atogepant.
Patient & Prescribing Data
Adults with chronic migraine
CGRP-targeted therapies are probably effective; consider individual response and tolerability.
Clinical Best Practices
- Encourage participation in larger independent trials for better comparative data.
- Assess long-term safety and efficacy of CGRP therapies.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
